Biotech Values

[jbog]

Mufaso,

I'll look at the data later but some of these small studies aren't defined completely.

Alt's terrible discontinuation rate was caused by not allowing the clinician to adjust the dose for tolerability. Alt's drop out was around the mid 25 % range without dose adjustment while Novo runs around 17% with dose adjustment. Alt's headline news was a disaster but what can it do with a variable dose?